Analiza wieloośrodkowa CAR (CAR-MA): badanie retrospektywne mające na celu scharakteryzowanie wyników komórek T CAR i związanych z nimi toksyczności u dzieci i młodych dorosłych z B-ALL
Study Description:
This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.
Objectives:
Primary
To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed
To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL
Secondary
To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. Completed
To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed
To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed
To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed
To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.
To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.
To evaluate the response of extramedullary disease following CAR T-cell therapy.
To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.
To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations.
To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.
To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.
To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).
To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).
To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.
Study Population and Source of Data: Subjects who were less than < 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL.
Przegląd badań
Status
Status
Warunki
Warunki
Szczegółowy opis
Study Description:
This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.
Objectives:
Primary
- To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
- To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL
Secondary
- To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. COMPLETED.
- To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
- To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
- To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
- To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.
- To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.
- To evaluate the response of extramedullary disease following CAR T-cell therapy.
- To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.
- To describe response, survival, and toxicities after CAR Tcell therapy in children with trisomy 21 and other important subpopulations.
- To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.
- To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.
- To describe response, survival, and toxicities after CAR Tcell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).
- To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).
- To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Maryland
-
Bethesda, Maryland, Stany Zjednoczone, 20892
- National Cancer Institute (NCI)
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Subjects who were less than or equal to 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL. This protocol will be amended to incorporate new research objectives and new data as necessary.
Opis
- Subjects will not be recruited for this study; however, up to 210 subjects records will be selected from treatment protocols who received CAR therapy for B-ALL. Subject who opted out of the future use of his/her data will be excluded. The subjects enrolled to a CAR T cell therapy treatment protocol within the Pediatric Oncology Branch unless, are < 25 years of age at the time of diagnosis and must have received prior a CAR T-cell product.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: RETROSPECTIVE
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
|---|
|
1
Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Response free survival (completed)
Ramy czasowe: 6 months
|
To evaluate the RFS at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. |
6 months
|
|
Outcome evaluation
Ramy czasowe: 12 months
|
To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL |
12 months
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Complete Response Rate (completed)
Ramy czasowe: 12 months
|
To evaluate the CR rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab |
12 months
|
|
Relapse Rate (completed)
Ramy czasowe: 12 months
|
To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab |
12 months
|
|
Response free survival (completed)
Ramy czasowe: 12 months
|
To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab |
12 months
|
|
Minimal Residual Disease detection (completed)
Ramy czasowe: 12 months
|
To evaluate the MRD negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab |
12 months
|
|
Impact of immunotherapies on CAR outcomes
Ramy czasowe: 12 months
|
To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes |
12 months
|
|
Cytopenias after CAR
Ramy czasowe: 12 months
|
To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T cell outcomes |
12 months
|
|
Response of extramedullary disease
Ramy czasowe: 12 months
|
To evlauate the response of extramedullary disease following CAR T cell therapy |
12 months
|
|
Frequency of malignant neoplasms
Ramy czasowe: 12 months
|
To evaluate the response of extramedullary disease following CAR T cell therapy |
12 months
|
|
Response, survival and toxicities in subpopulations
Ramy czasowe: 12 months
|
To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations. |
12 months
|
|
Impact of next generation sequencing MRD and duration of B cell aplasia
Ramy czasowe: 12 months
|
To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes. |
12 months
|
|
Frequency of infections
Ramy czasowe: 12 months
|
To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy. |
12 months
|
|
Response, survival and toxicities after CAR
Ramy czasowe: 12 months
|
To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy) |
12 months
|
|
Compare toxicities and outcomes across CAR constructs
Ramy czasowe: 12 months
|
To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.) |
12 months
|
|
Impact of CAR on other health-related outcomes
Ramy czasowe: 12 months
|
To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes |
12 months
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: Sara K Silbert, M.D., National Cancer Institute (NCI)
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Rzeczywisty)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Procesy patologiczne
- Nowotwory
- Atrybuty choroby
- Choroby układu odpornościowego
- Nowotwory według typu histologicznego
- Choroby hematologiczne
- Choroby limfatyczne
- Zaburzenia limfoproliferacyjne
- Zaburzenia immunoproliferacyjne
- Białaczka, układ limfatyczny
- Białaczka
- Stany patologiczne, oznaki i objawy
- Choroby hemowe i limfatyczne
- Nawrót
- Prekursorowa komórkowa białaczka limfoblastyczna-chłoniak
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 10000651
- 000651-C
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
All IPD recorded in the medical record will be shared with intramural investigators upon request.
Ramy czasowe udostępniania IPD
Clinical data available during the study and indefinitely.
Kryteria dostępu do udostępniania IPD
Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .